The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study

Dupilumab is prescribed in one dosage across adult atopic dermatitis patients. Differences in drug exposure may explain variation in treatment response. Investigating the clinical relevance of dupilumab serum concentration in atopic dermatitis in real-world practice. In two centers (Netherlands, UK)...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2023-12, Vol.34 (1), p.2193663-2193663
Main Authors: Bosma, Angela L., Gerbens, Louise A. A., El Khattabi, Hajar, Loeff, Floris C., Duckworth, Michael, Woolf, Richard T., Rispens, Theo, Smith, Catherine H., Spuls, Phyllis I.
Format: Article
Language:English
Subjects:
Adult
Atopic dermatitis
Clinical Relevance
Dermatitis, Atopic - drug therapy
Double-Blind Method
dupilumab
Humans
Injections, Subcutaneous
Prospective Studies
serum concentration
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dupilumab is prescribed in one dosage across adult atopic dermatitis patients. Differences in drug exposure may explain variation in treatment response. Investigating the clinical relevance of dupilumab serum concentration in atopic dermatitis in real-world practice. In two centers (Netherlands, UK), adults treated with dupilumab for atopic dermatitis were evaluated for effectiveness and safety pretreatment and at 2, 12, 24, and 48 weeks; trough serum samples were analyzed for dupilumab concentration at corresponding time points. In 149 patients, median dupilumab levels during follow-up ranged from 57.4 to 72.4 μg/mL. Levels showed high inter-patient and low intra-patient variability. No correlation was found between levels and ΔEASI. At 2 weeks, levels of ≥64.1 μg/mL predict EASI ≤7 at 24 weeks (specificity:100%, sensitivity:60%; p = .022). At 12 weeks, ≤32.7 μg/mL predicts EASI >7 at 24 weeks (sensitivity:95%, specificity:26%; p = .011). Inverse correlations were found between baseline EASI and levels at 2, 12, and 24 weeks (r = −0.25 to 0.36; p ≤ .023). Low levels were particularly observed in patients with adverse events, treatment interval deviation, and discontinuation. At the on-label dosage, the measured range of dupilumab levels does not seem to yield differences in treatment effectiveness. However, disease activity does seem to influence dupilumab levels - higher baseline disease activity results in lower levels at follow-up.
ISSN:0954-6634
1471-1753
DOI:10.1080/09546634.2023.2193663